ELAVL1 and cancer: In the context of small molecules, besides the small molecule inhibitors recently reviewed (D'agostino et al., 2019), we highlight novel indole derivatives tested in models of retinal endothelial cells (Platania et al., 2020), the suramin tested in oral cancer cells (Kakuguchi et al., 2018), the azaphilone‐9 tested in biochemical settings (Kaur et al., 2017), and tanshinone mimics tested in different cancer cells (Manzoni et al., 2018) using specific RNA targets as a readout of HuR activity.